Evidence map›Paper›PMID 33661992›Full record

SynthesisPloS one2021

Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.

Adam Booth, Angus Bruno Reed, Sonia Ponzo, Arrash Yassaee, Mert Aral, David Plans, Alain Labrique, Diwakar Mohan

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05181696 (Radiographic Severity Scoring System and Clinical and Laboratory Evolution of COVID-19 Pneumonia), which is not on this map. Cited by 329 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
329citing papers in PubMed, 8 pooled it
32.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05181696 unknown statusnot on this map

Radiographic Severity Scoring System and Clinical and Laboratory Evolution of COVID-19 Pneumonia

TypeobservationalSponsorOsijek University HospitalRan2020 to 2025Enrolled200ConditionsCOVID-19 Pneumonia, Sepsis, SARS-CoV-2 Acute Respiratory Disease, PneumoniaArmsChest X-ray
3 · Its place in the literature

Who cites it

329 citing papers in PubMed, 8 syntheses or guidelines pooled it, 552 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Risk of serious COVID-19 outcomes among adults and children with moderate-to-severe asthma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  8. Pooled it
  9. Trial
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

269 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Adam BoothHuma Therapeutics Limited, London, United Kingdom.
Angus Bruno ReedHuma Therapeutics Limited, London, United Kingdom.
Sonia PonzoHuma Therapeutics Limited, London, United Kingdom.
Arrash YassaeeHuma Therapeutics Limited, London, United Kingdom.
Mert AralHuma Therapeutics Limited, London, United Kingdom.
David PlansHuma Therapeutics Limited, London, United Kingdom.ORCID 0000-0002-0476-3342
Alain LabriqueJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Diwakar MohanJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Johns Hopkins University · USUniversity of Exeter · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimCOVID-19 clinical presentation is heterogeneous, ranging from asymptomatic to severe cases. While there are a number of early publications relating to risk factors for COVID-19 infection, low sample size and heterogeneity in study design impacted consolidation of early findings. There is a pressing need to identify the factors which predispose patients to severe cases of COVID-19. For rapid and widespread risk stratification, these factors should be easily obtainable, inexpensive, and avoid invasive clinical procedures. The aim of our study is to fill this knowledge gap by systematically mapping all the available evidence on the association of various clinical, demographic, and lifestyle variables with the risk of specific adverse outcomes in patients with COVID-19.

methodsThe systematic review was conducted using standardized methodology, searching two electronic databases (PubMed and SCOPUS) for relevant literature published between 1st January 2020 and 9th July 2020. Included studies reported characteristics of patients with COVID-19 while reporting outcomes relating to disease severity. In the case of sufficient comparable data, meta-analyses were conducted to estimate risk of each variable.

resultsSeventy-six studies were identified, with a total of 17,860,001 patients across 14 countries. The studies were highly heterogeneous in terms of the sample under study, outcomes, and risk measures reported. A large number of risk factors were presented for COVID-19. Commonly reported variables for adverse outcome from COVID-19 comprised patient characteristics, including age >75 (OR: 2.65, 95% CI: 1.81-3.90), male sex (OR: 2.05, 95% CI: 1.39-3.04) and severe obesity (OR: 2.57, 95% CI: 1.31-5.05). Active cancer (OR: 1.46, 95% CI: 1.04-2.04) was associated with increased risk of severe outcome. A number of common symptoms and vital measures (respiratory rate and SpO2) also suggested elevated risk profiles.

conclusionsBased on the findings of this study, a range of easily assessed parameters are valuable to predict elevated risk of severe illness and mortality as a result of COVID-19, including patient characteristics and detailed comorbidities, alongside the novel inclusion of real-time symptoms and vital measurements.

Indexed as

Age FactorsComorbidityCOVID-19FemaleHumansMaleNeoplasmsObesityRisk FactorsSARS-CoV-2Severity of Illness IndexSex Factors

Identifiers

PMID33661992
PMCPMC7932512
OpenAlexW3134061302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.